Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

Michelle Meyer, Delphine Malherbe, Alexander Bukreyev

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

Original languageEnglish (US)
JournalTrends in Microbiology
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Ebola Vaccines
Ebolavirus
Vaccines
Clinical Trials
Disease Outbreaks
Vaccination
Animal Models
Antibodies

Keywords

  • Ebola
  • immune correlates
  • immunity
  • protection
  • vaccine

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

Can Ebola Virus Vaccines Have Universal Immune Correlates of protection? / Meyer, Michelle; Malherbe, Delphine; Bukreyev, Alexander.

In: Trends in Microbiology, 01.01.2018.

Research output: Contribution to journalArticle

Meyer, Michelle ; Malherbe, Delphine ; Bukreyev, Alexander. / Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?. In: Trends in Microbiology. 2018.
@article{1dbaf8510e714029a74a3b73d4b90f9f,
title = "Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?",
abstract = "Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.",
keywords = "Ebola, immune correlates, immunity, protection, vaccine",
author = "Michelle Meyer and Delphine Malherbe and Alexander Bukreyev",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.tim.2018.08.008",
language = "English (US)",
journal = "Trends in Microbiology",
issn = "0966-842X",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

AU - Meyer, Michelle

AU - Malherbe, Delphine

AU - Bukreyev, Alexander

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

AB - Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethical reasons and the sporadic nature of outbreaks. For such situations, the ‘animal rule’ was established, requiring the product be tested in animal models, expected to predict the response observed in humans. For vaccines, this testing aims to identify immune correlates of protection, such as antibody or cell-mediated responses. In the wake of the 2013–2016 EBOV epidemic, and despite advancement of promising candidates into clinical trials, protective correlates remain ambiguous. In the hope of identifying a reliable correlate by comparing preclinical and clinical trial data on immune responses to vaccination, we conclude that correlates are not universal for all EBOV vaccines.

KW - Ebola

KW - immune correlates

KW - immunity

KW - protection

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85052922298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052922298&partnerID=8YFLogxK

U2 - 10.1016/j.tim.2018.08.008

DO - 10.1016/j.tim.2018.08.008

M3 - Article

JO - Trends in Microbiology

JF - Trends in Microbiology

SN - 0966-842X

ER -